A study on the pharmacokinetics and pharmacodynamics of remimazolam during total intravenous anesthesia with remifentanil

Evaluation pharmacokinetics and pharmacodynamics of remimazolam during total intravenous anesthesia with remifentanil in patients underwent surgery

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0007066

Enrollment

Registered

2022-03-10

Start date

2022-03-02

Completion date

Unknown

Last updated

2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Induce anesthesia by remimazolam injected with vein to 6mg/kg/hr rate continuously until loss of consciousness. After the patient's consciousness is lost, the rate of injecting remimazolam is c

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: the patients who undergoing general anesthesia during regular surgery at Busan Paik Hospital, aged 18 to 85 and rated 1 to 3 class by the American Society of Anesthesia classification

Exclusion criteria

Exclusion criteria: Patients with difficulty in communication, hypersensitivity to benzodiazepine or flumagenyl, neurological disorders (such as cognitive impairment, dementia etc.) that may affect cognitive function, past history within three months or current use of drugs that affect the central nervous system (such as antipsychotics, antidepressants, anti-anxiety drugs, anticonvulsants, etc.), alcohol addiction within two years, a history of alcohol dependence

Design outcomes

Primary

Measure	Time frame
blood concentration of remimazolam	—

Countries

Korea, Republic of

Contacts

Public ContactBEOMSEOK CHOI

Inje University Busan Paik Hospital

timeight8@gmail.com+82-51-890-6520

Outcome results